Search results

Skip to results

Type

Status

Last updated

Showing 1 to 3 of 3 results for entrectinib-ros1-positive advanced non-small-cell lung cancer

  1. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA643

  2. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)

    Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    4 December 2024
    View recommendations

    Sections for TA1021

  3. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children over 12 years.

    Technology appraisal guidance
    Published
    12 August 2020
    View recommendations

    Sections for TA644